Hit HIV-1 hard, but only when necessary

Randomised, controlled trial data show that combination antiretroviral therapy for HIV-1 infection benefits people with CD4-cell counts less than 350 cells/microL. Based on currently known risks and benefits, we believe that if CD4-cell counts and viral load are monitored carefully, and highly active antiretroviral therapy (HAART) is started commonly when the CD4-cell count drops below 350 cells/microL, then clinically relevant immune-system damage and progression to AIDS and death can be greatly delayed or prevented. This approach is dictated by three features of HIV-1 infection that are not typical of infectious diseases: no available regimen can eradicate HIV-1; all currently effective regimens may cause undesirable, sometimes life-threatening, toxic effects; and, unless regimens are strictly adhered to, multidrug resistance can develop, limiting future treatment options. If therapy is started too early, cumulative side-effects of the drugs used and the development of multidrug resistance may outweigh the net benefits of the lengthening of life. If therapy is started too late, increases in disease progression and mortality outweigh the risk of adverse events. A patients' activist (MH) and a clinician (CCJC) discuss data that justify this balanced approach and the feasibility of randomised controlled trials to provide clearer answers about when to start treatment.

[1]  C. Fox,et al.  Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. , 2000, The Journal of clinical investigation.

[2]  J. Coffin,et al.  Linkage disequilibrium test implies a large effective population number for HIV in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[4]  Calvin Cohen,et al.  Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease , 1998, The Lancet.

[5]  J. Phair,et al.  The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. , 1990, The New England journal of medicine.

[6]  C. Berg,et al.  Abortion surveillance--United States, 1999. , 2002, Morbidity and mortality weekly report. Surveillance summaries.

[7]  C. Grunfeld,et al.  Fat distribution and metabolic changes in patients with HIV infection. , 1999, AIDS.

[8]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[9]  D. Cooper,et al.  Therapeutic strategies for HIV infection--time to think hard. , 1998, The New England journal of medicine.

[10]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.

[11]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[12]  D. Ho,et al.  Perspectives series: host/pathogen interactions. Dynamics of HIV-1 replication in vivo. , 1997, The Journal of clinical investigation.

[13]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[14]  J. Metcalf,et al.  Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. , 1999, JAMA.

[15]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[16]  A. Mocroft,et al.  Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection , 1999, The Lancet.

[17]  N. Low,et al.  Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. , 1999, AIDS.

[18]  Louis J. Picker,et al.  Changes in thymic function with age and during the treatment of HIV infection , 1998, Nature.

[19]  B Wise,et al.  Antiretroviral therapy in adults. , 1996, Journal of the American Academy of Nurse Practitioners.

[20]  C. Pitcher,et al.  HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression , 1999, Nature Medicine.

[21]  J. Gallant,et al.  Strategies for long-term success in the treatment of HIV infection. , 2000, JAMA.

[22]  J. McCune,et al.  Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1 , 1998, Nature Medicine.

[23]  A. Fauci,et al.  Benchmarks for antiretroviral therapy. , 2000, The Journal of clinical investigation.

[24]  S. Hammer,et al.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.

[25]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[26]  J A Fleishman,et al.  Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. , 1999, JAMA.

[27]  M. Zupancic,et al.  Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.

[29]  D. Ho.  DYNAMICS OF HIV-1 REPLICATION IN VIVO , 1997 .